Insamo's $12M Seed Funding Sparks Innovation in Biotechnology
February 23, 2024, 7:16 am
Insamo, a Berkeley-based biotechnology company, recently secured $12 million in seed funding, igniting excitement in the industry. Led by a team of visionaries, including Tim Craven, Toby Passioura, and Glen McIntyre, Insamo is revolutionizing the field with its groundbreaking approach to membrane-permeable and orally available cyclic-peptides.
The funding round, which included key investors like Playground Global, venBio, and MRL Ventures Fund, will fuel Insamo's expansion efforts and propel its development initiatives. With a focus on enhancing patient care and driving rapid drug discovery, Insamo's innovative platform combines cutting-edge technology with a deep commitment to improving healthcare outcomes.
By leveraging ML-driven molecular design, ultra high-throughput molecular biology, and parallel synthetic chemistry, Insamo is able to identify preclinical candidates with antibody-like binding affinity. This unique approach allows the company to generate treatment candidates from scratch, offering new hope for patients with currently intractable drug targets.
With research sites in both Berkeley, CA and Sydney, Australia, Insamo is poised to make a lasting impact on the biotechnology landscape. The company's ability to create easily administered oral cyclic-peptide formulations represents a significant advancement in the field, potentially replacing traditional injected or infused biologics.
As Insamo continues to push the boundaries of biotechnology, the industry eagerly anticipates the transformative solutions that will emerge from this innovative company. With a focus on driving innovation and improving patient outcomes, Insamo's $12 million seed funding marks the beginning of a new era in biotechnology.
The funding round, which included key investors like Playground Global, venBio, and MRL Ventures Fund, will fuel Insamo's expansion efforts and propel its development initiatives. With a focus on enhancing patient care and driving rapid drug discovery, Insamo's innovative platform combines cutting-edge technology with a deep commitment to improving healthcare outcomes.
By leveraging ML-driven molecular design, ultra high-throughput molecular biology, and parallel synthetic chemistry, Insamo is able to identify preclinical candidates with antibody-like binding affinity. This unique approach allows the company to generate treatment candidates from scratch, offering new hope for patients with currently intractable drug targets.
With research sites in both Berkeley, CA and Sydney, Australia, Insamo is poised to make a lasting impact on the biotechnology landscape. The company's ability to create easily administered oral cyclic-peptide formulations represents a significant advancement in the field, potentially replacing traditional injected or infused biologics.
As Insamo continues to push the boundaries of biotechnology, the industry eagerly anticipates the transformative solutions that will emerge from this innovative company. With a focus on driving innovation and improving patient outcomes, Insamo's $12 million seed funding marks the beginning of a new era in biotechnology.